Second U.S. jury finds AbbVie misrepresented risks of AndroGel

(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

from Reuters: U.S. http://ift.tt/2fNYaAv